Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.
|Motif Bio Announces FDA Acceptance of New Drug Application with Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections|
August 14, 2018
|Motif Bio to Present at Investor Events in August and September|
August 9, 2018
|Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037|
August 8, 2018